S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

G1 Therapeutics Short Interest Ratio and Short Volume

-0.59 (-6.05%)
(As of 01/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.02 million shs
Average Volume
904,333 shs
Market Capitalization
$389.93 million
P/E Ratio
Dividend Yield

G1 Therapeutics (NASDAQ:GTHX) Short Interest Data

Current Short Volume
Previous Short Volume
Change Vs. Previous Month
Dollar Volume Sold Short
$90.08 million
Short Interest Ratio / Days to Cover
Last Record Date
January, 15 2022
Outstanding Shares
Percentage of Shares Shorted
Today's Trading Volume
Average Trading Volume
Today's Volume Vs. Average
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling G1 Therapeutics ?

Sign up to receive the latest short interest report for G1 Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

G1 Therapeutics (NASDAQ:GTHX) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/15/20228,910,000 shares $90.08 million -1.0%N/A9.8 $10.11
12/31/20219,000,000 shares $91.89 million -3.1%27.4%10 $10.21
12/15/20219,290,000 shares $99.12 million +2.9%28.3%9.6 $10.67
11/30/20219,030,000 shares $116.49 million +0.8%27.5%9.6 $12.90
11/15/20218,960,000 shares $130.91 million +0.9%26.6%9.9 $14.61
10/29/20218,880,000 shares $128.67 million +5.2%26.3%9.8 $14.49
10/15/20218,440,000 shares $107.78 million -6.4%25.1%9.7 $12.77
9/30/20219,020,000 shares $121.05 million +22.7%26.9%8.8 $13.42
9/15/20217,350,000 shares $102.46 million -3.7%21.9%7.4 $13.94
8/31/20217,630,000 shares $115.37 million +1.2%22.8%7.3 $15.12
8/13/20217,540,000 shares $108.27 million +2.6%22.5%6.7 $14.36
7/30/20217,350,000 shares $127.23 million +20.1%21.9%6.6 $17.31
7/15/20216,120,000 shares $116.89 million +5.0%18.4%5.3 $19.10
6/30/20215,830,000 shares $127.91 million -2.7%17.5%5.7 $21.94
6/15/20215,990,000 shares $130.88 million -4.8%18.0%5.9 $21.85
5/28/20216,290,000 shares $136.62 million -2.2%18.9%6.3 $21.72
5/14/20216,430,000 shares $133.04 million -8.8%19.3%5.8 $20.69
4/30/20217,050,000 shares $154.54 million +1.3%21.1%4.9 $21.92
4/15/20216,960,000 shares $171.91 million -6.5%21.1%4.6 $24.70
3/31/20217,440,000 shares $171.05 million -2.9%23.3%4.7 $22.99
3/15/20217,660,000 shares $178.86 million +21.0%24.0%5 $23.35
2/26/20216,330,000 shares $141.57 million +21.3%20.5%3.9 $22.37
2/12/20215,220,000 shares $170.12 million -3.0%18.7%3.2 $32.59
1/29/20215,380,000 shares $121.37 million -10.8%19.4%3.8 $22.56
1/15/20216,030,000 shares $124.64 million -9.5%21.8%4.6 $20.67

G1 Therapeutics (NASDAQ:GTHX) Short Interest Frequently Asked Questions

What is G1 Therapeutics' current short interest?

Short interest is the volume of G1 Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 15th, investors have sold 8,910,000 shares of GTHX short. Learn More on G1 Therapeutics' current short interest.

What is a good short interest ratio for G1 Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. G1 Therapeutics currently has a short interest ratio of 10.0. Learn More on a good short interest ratio for G1 Therapeutics

Which institutional investors are shorting G1 Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of G1 Therapeutics: National Bank of Canada FI, Jane Street Group LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is G1 Therapeutics' short interest increasing or decreasing?

G1 Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 8,910,000 shares, a decline of 1.0% from the previous total of 9,000,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does G1 Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to G1 Therapeutics: Travere Therapeutics, Inc. (8.54%), Supernus Pharmaceuticals, Inc. (14.50%), Cassava Sciences, Inc. (34.82%), Prothena Co. plc (0.00%), Zogenix, Inc. (11.15%), Dynavax Technologies Co. (0.00%), IVERIC bio, Inc. (0.00%), Morphic Holding, Inc. (6.09%), Bicycle Therapeutics plc (0.00%), and Erasca Inc (11.96%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($8.74 billion), S&P Global Inc. ($7.90 billion), Charter Communications, Inc. ($5.88 billion), Lucid Group Inc ($3.75 billion), Palo Alto Networks, Inc. ($3.44 billion), Wayfair Inc. ($2.88 billion), Rivian ($2.60 billion), Zscaler, Inc. ($1.86 billion), ViacomCBS Inc. ($1.82 billion), and Match Group, Inc. ($1.79 billion). View all of the most shorted stocks.

What does it mean to sell short G1 Therapeutics stock?

Short selling GTHX is an investing strategy that aims to generate trading profit from G1 Therapeutics as its price is falling. G1 Therapeutics' stock is trading down $0.59 today. To short G1 Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that G1 Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against G1 Therapeutics?

A short squeeze for G1 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GTHX, which in turn drives the price of the stock up even further.

How often is G1 Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTHX, twice per month. The most recent reporting period available is January, 15 2022.

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.